4-(6-(4-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)morpholine

Catalog No. :
ACRVIF464
CAS No. :
1189882-02-7
Molecular Formula :
C21H27N5O5S
Molecular Weight :
461.54

IUPAC Name:4-(6-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)morpholine

4-(6-(4-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)morpholine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4-(6-(4-((2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)morpholine
IUPAC Name4-(6-(4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)sulfonyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)morpholine
Molecular FormulaC21H27N5O5S
Molecular Weight461.54
SMILESO=S(N1CCN(C2=CC(N3CCOCC3)=NC(C)=N2)CC1)(C4=CC5=C(C=C4)OCCO5)=O
InChI KeyBJSKJXLTRNDPGC-UHFFFAOYSA-N
CAS No.1189882-02-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACRVIF464 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFQPJ490 route compound structure diagram
    ACFQPJ49063758-12-3 In Stock
  4. Then
  5. ACRVIF464 route product structure diagram
    ACRVIF4641189882-02-7
Inquiry

2. ACRVIF464 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRVIF464 route product structure diagram
    ACRVIF4641189882-02-7
Inquiry

Comments (0)